Literature DB >> 22337635

A practical comparison of blinded methods for sample size reviews in survival data clinical trials.

Susan Todd1, Elsa Valdés-Márquez, Jodie West.   

Abstract

This paper presents practical approaches to the problem of sample size re-estimation in the case of clinical trials with survival data when proportional hazards can be assumed. When data are readily available at the time of the review, on a full range of survival experiences across the recruited patients, it is shown that, as expected, performing a blinded re-estimation procedure is straightforward and can help to maintain the trial's pre-specified error rates. Two alternative methods for dealing with the situation where limited survival experiences are available at the time of the sample size review are then presented and compared. In this instance, extrapolation is required in order to undertake the sample size re-estimation. Worked examples, together with results from a simulation study are described. It is concluded that, as in the standard case, use of either extrapolation approach successfully protects the trial error rates.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22337635     DOI: 10.1002/pst.516

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  3 in total

1.  SpHincterotomy for Acute Recurrent Pancreatitis Randomized Trial: Rationale, Methodology, and Potential Implications.

Authors:  Gregory A Coté; Valerie L Durkalski-Mauldin; Jose Serrano; Erin Klintworth; April W Williams; Zobeida Cruz-Monserrate; Mustafa Arain; James L Buxbaum; Darwin L Conwell; Evan L Fogel; Martin L Freeman; Timothy B Gardner; Erwin van Geenen; J Royce Groce; Sreenivasa S Jonnalagadda; Rajesh N Keswani; Shyam Menon; Dana C Moffatt; Georgios I Papachristou; Andrew Ross; Paul R Tarnasky; Andrew Y Wang; C Mel Wilcox; Frank Hamilton; Dhiraj Yadav
Journal:  Pancreas       Date:  2019-09       Impact factor: 3.327

2.  Adaptive graph-based multiple testing procedures.

Authors:  Florian Klinglmueller; Martin Posch; Franz Koenig
Journal:  Pharm Stat       Date:  2014-10-16       Impact factor: 1.894

3.  Targeted survival improvements in clinical trials: are you an absolutist or relativist?

Authors:  James Paul
Journal:  Cancer       Date:  2014-10-02       Impact factor: 6.860

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.